Prior studies have shown that FKBP5 is highly expressed across multiple tissues and significantly contributes to drug resistance in various cancers, including breast and prostate cancers, multiple myeloma, acute lymphoblastic leukemia, and melanoma (44). This evidence concerns the gene FKBP5 and Familial prostate cancer.